Healthpoint Biotherapeutics today announced that the results for its Phase 2b clinical trial investigating the efficacy of HP802-247 in venous leg ulcers is published on The Lancet, beginning August 3, 2012, with Online First access to the article, followed by print publication in the next issue. HP802-247 is an investigational allogeneic living cell bioformulation containing keratinocytes and fibroblasts currently under development for the treatment of venous leg ulcers.
"We are very pleased that the trial results are appearing in such a prestigious general medical journal, thus recognizing the impact chronic wounds have across multiple medical specialties," commented Bert Slade, MD, FAAAAI, Chief Medical Officer at Healthpoint Biotherapeutics.
Venous leg ulcers affect approximately 2.5 million Americans and are associated with impaired circulation most commonly resulting from damaged veins and/or valves. They typically appear as an open lesion, or ulcer, on the lower extremities, are very slow to heal and often reoccur due to the chronic nature of the underlying disease process.